SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽DemoℹVision

What are the optimal timing windows for TREM2 agonism vs antagonism across disease progression stages?

PARTIALLY ADDRESSED

The debate highlighted that TREM2 therapeutic targeting remains contested across disease stages, but no clear framework exists for when to activate versus inhibit TREM2 signaling. This timing question is critical for clinical translation but remains empirically unresolved. Source: Debate session sess_SDA-2026-04-02-gap-001 (Analysis: SDA-2026-04-02-gap-001)

Priority: 0.90 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: What are the optimal timing windows for TREM2 agonism vs antagonism across disease progression stages? is a 0.9 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What are the optimal timing windows for TREM2 agonism vs antagonism across disease progression stages? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (10)

TREM2→AlzheimerTREM2→ALZHEIMER'S DISEASETREM2→NeuroinflammationMICROGLIA→TREM2TREM2→ALZHEIMER
▸ Show 5 more

associated with (14)

TREM2→ALZHEIMER'S DISEASETREM2→MICROGLIAALZHEIMER'S DISEASE→TREM2TREM2→neurodegenerationAMYLOID→TREM2
▸ Show 9 more

data in (8)

ad_genetic_risk_loci:TREM2→TREM2benchmark_ot_ad_answer_key:TREM2→TREM2TREM2→benchmark_ot_ad_answer_key:TREM2ds-db4a006ea647→TREM2ds-f50762b67605→TREM2
▸ Show 3 more

expressed in (3)

TREM2→AlzheimerTREM2→MICROGLIAMICROGLIA→TREM2

inhibits (1)

TREM2→Inflammation

provides data for (5)

TREM2→ds-83b31ef18d49TREM2→ds-6784494f1741TREM2→ds-db4a006ea647TREM2→ds-f50762b67605TREM2→ds-f2c28aed24a7

regulates (2)

TREM2→MICROGLIATREM2→Alzheimer

relates to (2)

h-immunity-c3bc272f→TREM2h-immunity-c64967ab→TREM2

therapeutic target (5)

TREM2→AlzheimerTREM2→NeuroinflammationTREM2→ALZHEIMER'S DISEASETREM2→ALZHEIMERTREM2→Inflammation
🕑 Activity Feed
✏ update on knowledge_gap by max_gmail 2026-04-28T00:18
✏ update on knowledge_gap by None 2026-04-25T22:15
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps